Clinical Trial Update: IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial of IMPT-514 in systemic lupus erythematosus, ANCA-associated vasculitis, and idiopathic inflammatory myopathy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Idiopathic Inflammatory Myopathy
• Systemic Lupus Erythematosus

Drugs mentioned

• IMPT-514

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV) | EARLY_Phase 1 | Status: TERMINATED